The search for safe and efficacious products to prevent severe respiratory syncytial virus
(RSV) disease in young infants has lasted more than 60 years. In high-income and middle …

Introduction Nirsevimab, a monoclonal antibody for the prevention of disease caused by
respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain …

In May 2023, the US FDA advisors endorsed Pfizer's pregnancy-administered vaccine
(branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection …

Summary Background Lower respiratory infections (LRIs) are a major global contributor to
morbidity and mortality. In 2020–21, non-pharmaceutical interventions associated with the …

Background New prevention strategies for respiratory syncytial virus (RSV) are emerging,
but it is unclear if they will be cost-effective in low-and middle-income countries. We …

Introducción Recientemente se ha aprobado en Europa y en España el uso de nirsevimab,
un anticuerpo monoclonal (AcM) para la prevención de la enfermedad por virus respiratorio …

Background New vaccines for pregnant women have recently been introduced in some high-
income countries to protect infants in early life. Implementing maternal immunisation (MI) …

Background. New interventions are available for the prevention of respiratory syncytial virus
(RSV) disease in young infants. We aimed to assess the potential impact and cost …

Monoclonal antibodies (mAbs) are revolutionizing management of non-communicable
diseases in high-income countries and are increasingly being advanced for a range of …

The current understanding of the RSV-related mortality age distribution in low-and lower-
middle-income countries (LMICs) relies on a limited number of disease incidence studies …